Laurus Labs Share Price: 87.9% CAGR in 3 Years as It Outpaces Divi’s, Gland Pharma and Sun Pharma
- November 10, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Laurus Labs Share Price: 87.9% CAGR in 3 Years as It Outpaces Divi’s, Gland Pharma and Sun Pharma
Laurus Labs previous close Rs 2,454. 3-year CAGR 87.9%. Up 6.6x since 9 Nov 2023. ROE 22.11%. Market cap Rs 1,32,376 crore.
Quick Answer
The Laurus Labs share price closed at Rs 2,454 on 9 November 2026, a compounded annual return of 87.9% over three years. That compares with Divi’s Laboratories at 49.0%, Gland Pharma at 27.0% and Sun Pharmaceutical Industries at 17.4%. The company has a market cap of Rs 1,32,376 crore and a P/E of 99.35 against an industry P/E of 40.13.
The Laurus Labs share price is among the strongest three-year runs in Indian pharma. Laurus Labs, the Hyderabad-based maker of active pharmaceutical ingredients that listed in 2019, has multiplied investor money more than six times, well ahead of larger and older drug companies.
We compare that record with Divi’s Laboratories, Gland Pharma and Sun Pharmaceutical Industries. The article calculates three-year CAGR for all four and sets the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.
Click Here – Get Free Investment Predictions
How Much Has the Laurus Labs Share Price Returned in 3 Years?
The Laurus Labs stock closed at Rs 369.70 on 9 November 2023 and at Rs 2,454.00 on 9 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 6.64 lakh, which is a CAGR of 87.9%. This is a price return and leaves out dividends.
CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Laurus Labs can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.
The Laurus Labs share price has also benefited from a low starting point: a stock that begins a period at a modest price can show a very large multiple when the business expands into new areas.
Laurus Labs vs Divi’s Laboratories, Gland Pharma and Sun Pharmaceutical Industries: 3-Year CAGR Compared
The table ranks the companies by three-year CAGR. Prices on 9 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 9 November 2026.
| Company | Close on 9 Nov 2023 | Previous close (9 Nov 2026) | Price multiple | 3-year CAGR |
|---|---|---|---|---|
| Laurus Labs | Rs 369.70 | Rs 2,454.00 | 6.6x | 87.9% |
| Divi’s Laboratories | Rs 3,498.50 | Rs 11,565.50 | 3.3x | 49.0% |
| Gland Pharma | Rs 1,612.65 | Rs 3,302.40 | 2.0x | 27.0% |
| Sun Pharmaceutical Industries | Rs 1,176.20 | Rs 1,904.50 | 1.6x | 17.4% |
The Laurus Labs stock leads the group at 87.9%, followed by Divi’s Laboratories at 49.0%, Gland Pharma at 27.0% and Sun Pharmaceutical Industries at 17.4%. Laurus Labs leads the group by a wide margin, with Divi’s Laboratories in second place. Sun Pharma, the largest by market cap, compounded at a steadier pace on a much larger base of capital.
Look at the Laurus Labs share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.
Valuation and Quality Compared
| Company | Market cap | P/E | Industry P/E | ROE | Debt to equity |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | Rs 4,57,073 crore | 41.60 | 40.13 | 13.79% | 0.04 |
| Divi’s Laboratories | Rs 3,07,147 crore | 91.33 | 40.13 | 15.32% | 0.00 |
| Laurus Labs | Rs 1,32,376 crore | 99.35 | 40.13 | 22.11% | 0.43 |
| Gland Pharma | Rs 54,476 crore | 44.08 | 40.13 | 11.57% | 0.02 |
By market cap, Sun Pharmaceutical Industries is the largest of the group at Rs 4,57,073 crore, while the Laurus Labs stock stands at Rs 1,32,376 crore, about 29% of that size. On earnings, Laurus Labs shares trade at a P/E of 99.35 against an industry P/E of 40.13, a premium of about 148%, which signals that the market expects faster earnings growth. Peer multiples are Divi’s Laboratories at 91.33, Gland Pharma at 44.08 and Sun Pharmaceutical Industries at 41.60.
Return on equity is 22.11% for the Laurus Labs stock, which ranks first among the four, and debt to equity stands at 0.43. Trailing EPS is Rs 24.66. Pharma companies that are scaling up new businesses often trade at high multiples, so P/E should be read together with return on equity and the pace of earnings growth.
What Is Driving the Laurus Labs Stock?
Laurus Labs makes active pharmaceutical ingredients, finished formulations, and contract development and manufacturing services. It built its name in antiretroviral ingredients and has been widening into oncology, other therapy areas and synthesis work.
The company has also invested in newer areas such as biotechnology services. A broader mix reduces reliance on a single product group and gives it more ways to grow.
Followers of the Laurus Labs share price usually track contract manufacturing orders, margins in the ingredients business, capacity additions and progress in newer segments.
How the Established Players Stack Up
Divi’s Laboratories is a Hyderabad-based maker of generic active ingredients and custom synthesis products, and it is among the largest names in the segment. It compounded at 49.0% a year, on a market cap of Rs 3,07,147 crore and an ROE of 15.32%.
Gland Pharma is a Hyderabad-based injectables specialist that supplies regulated markets. It compounded at 27.0% a year, on a market cap of Rs 54,476 crore and an ROE of 11.57%.
Sun Pharmaceutical Industries is one of the largest pharma companies in India, with a broad generics and specialty portfolio. It compounded at 17.4% a year, on a market cap of Rs 4,57,073 crore and an ROE of 13.79%.
What Should Investors Track Next?
Three things are worth watching on the Laurus Labs share price. First, the growth of contract development and manufacturing work. Second, margins as capacity is added. Third, the progress of newer businesses such as biotechnology services.
At a P/E of 99, the market already expects very strong growth. Earnings in this space can be uneven, so size any position with that in mind.
Check the Univest Screener for live fundamentals of pharma stocks
How to Compare Pharma Stocks Yourself
You can repeat this exercise for any pair of stocks, including the Laurus Labs stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.
A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Laurus Labs share price, the same four checks give a more complete picture than price alone.
Download the Univest iOS App or Univest Android App to track the Laurus Labs share price and compare pharma stocks live.
A Remarkable Run That Now Needs Earnings to Keep Pace
The Laurus Labs share price compounded at 87.9% a year over three years, ahead of Divi’s at 49.0%, Gland Pharma at 27.0% and Sun Pharma at 17.4%. Its ROE of 22.11% is the highest of the four.
Divi’s brings a long record in ingredients, Gland Pharma offers an injectables focus, and Sun Pharma brings scale and diversification. The choice depends on how much valuation risk you are comfortable with.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Laurus Labs share price today?
Ans. Laurus Labs closed at Rs 2,454 on 9 November 2026, according to NSE data. It has a market cap of Rs 1,32,376 crore and a P/E of 99.35. Check live quotes before acting, as prices change every trading day.
What is the 3-year CAGR of the Laurus Labs stock?
Ans. Laurus Labs delivered a price CAGR of 87.9% over three years, moving from Rs 369.70 on 9 November 2023 to Rs 2,454.00 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.
Is Laurus Labs better than Divi’s Laboratories?
Ans. The Laurus Labs stock delivered a higher three-year CAGR at 87.9% than Divi’s at 49.0%. Divi’s is larger by market cap at Rs 3,07,147 crore, while Laurus Labs has the higher ROE at 22.11% against 15.32%. Both trade at premium multiples, so the better choice depends on your view of growth.
What does Laurus Labs do?
Ans. Laurus Labs is a Hyderabad-based pharmaceutical company that makes active pharmaceutical ingredients, finished formulations and offers contract development and manufacturing services.
Is the Laurus Labs stock debt free?
Ans. The debt to equity ratio of the Laurus Labs stock is 0.43 and its return on equity is 22.11%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.
Is Laurus Labs expensive compared with the industry?
Ans. Laurus Labs trades at a P/E of 99.35 against an industry P/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.
Which pharma stock gave the highest return in 3 years?
Ans. Among the companies compared here, Laurus Labs delivered the highest three-year CAGR at 87.9%, followed by Divi’s Laboratories at 49.0%. Past returns do not guarantee future performance.
How do I calculate CAGR for a stock?
Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.
